<DOC>
	<DOC>NCT02565732</DOC>
	<brief_summary>This is a safety and efficacy study of botulinum toxin type A in subjects with primary axillary hyperhidrosis.</brief_summary>
	<brief_title>Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis</brief_title>
	<detailed_description />
	<mesh_term>Hyperhidrosis</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Primary axillary hyperhidrosis Female or male, 18 years of age or older in good general health Excessive sweating interferes with daily life activities and scores 3 or 4 on the HDSS at Screening and Baseline Axillary sweat production of at least 50 mg/5 min measured gravimetrically Any neurological condition, that may place the subject at increased risk with exposure to botulinum toxin type A such as amyotrophic lateral sclerosis and motor neuropathy, LambertEaton syndrome, and Myasthenia gravis Muscle weakness or paralysis, particularly in the upper extremities Active skin disease or irritation or disrupted barrier at the treatment area Undergone any procedures which may affect the axillary areas Treatment with botulinum toxin type A in the axilla in the last 9 months or anywhere in the body in the last 6 months Any prior axillary use of an antihyperhidrosis medical device If menopausal had symptoms of menopause such as sweating or flushing within the last year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>